Option chain shows key data for NMC HEALTH PLC ORD by NMC Health Plc.'s stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for NMC HEALTH PLC ORD by NMC Health Plc..

NMC HEALTH PLC ORD by NMC Health Plc. (OTC:NMMCF) Stock, Option Chain

News

Intraday Update

Markets

Movers

Trading Ideas

ABEV

AFFINITY BEVERAGE GROUP by Affinity Beverage Group, Inc.

ABVG

ACST

AMRB

ANGO

APYP

AROC

AWCMY

BIOIF

BLPH

BNFT

BORR

CASI

CURATIVE BIOSCIENCES INC by Curative Biosciences, Inc.

CBDX

CBDY

CDEV

CEQP

CGOTF

CHMG

CNXS

COVTY

CVGW

DNOW

DRRSF

ECAOF

ECMXF

ECOL

EEVVF

EJPRY

EOLS

ETRN

EXTN

FANG

FARYF

FNKO

FRLF

GALT

GGBXF

GGLT

GGTTF

GIGNF

GLBS

GLNG

GMLP

GPOR

HEXO

HNRG

HRCXF

HUSKF

JMEI

JMPLF

KAYS

KELYA

KEQU

KKPNY

KRKR

LIFZF

LQDT

MBRX

MFCSF

MGMLF

MICWF

MPLX

MRNJ

MRQRF

MTRX

MTSC

MZDAY

NEPT

NINOY

NSANY

NSPDF

NTGR

Stocks That Hit 52-Week Lows On Monday

NMC HEALTH PLC ORD by NMC Health Plc.

Deutsche Bank analyst Stephen Powers maintains Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) with a Hold and lowers the price target from $67 to $62.

Price Target

Analyst Ratings

MDLZ

Deutsche Bank Maintains Hold on Mondelez International, Lowers Price Target to $62

RVSN

Rail Vision Announced The Signing Of A Binding Memorandum Of Understanding With Sujan Ventures, A Division Of The Esteemed Sujan Group To The Indian Rail Industry

Northland Capital Markets analyst Michael Latimore maintains Gorilla Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) with a Outperform and raises the price target from $13 to $18.

GRRR

Northland Capital Markets Maintains Outperform on Gorilla Tech Gr, Raises Price Target to $18

Barclays analyst Jason Goldberg maintains Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) with a Underweight and raises the price target from $59 to $61.

ZION

Barclays Maintains Underweight on Zions Bancorp, Raises Price Target to $61

Northland Capital Markets analyst Gus Richard reiterates Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Outperform and raises the price target from $144 to $160.

Reiteration

Northland Capital Markets Reiterates Outperform on Seagate Tech Hldgs, Raises Price Target to $160

REKR

Rekor Systems' AI-Powered Scout Platform Secures Role In $13M New Jersey Public Safety Upgrade

WIIM

AGYS

Agilysys shares are trading lower after the company reported worse-than-expected Q3 sales results and issued FY25 revenue guidance below estimates.

HC Wainwright &amp; Co. analyst Robert Burns maintains Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) with a Buy and raises the price target from $17 to $21.

REPL

HC Wainwright & Co. Maintains Buy on Replimune Group, Raises Price Target to $21

Barclays analyst Nicholas Campanella maintains Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) with a Overweight and lowers the price target from $71 to $69.

Barclays Maintains Overweight on Xcel Energy, Lowers Price Target to $69

Barclays analyst Benjamin Budish maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Overweight and raises the price target from $95 to $96.

SCHW

Barclays Maintains Overweight on Charles Schwab, Raises Price Target to $96

COHR

Coherent Announces The Launch Of New Pin-hole Array Biochips For Medical Diagnostics, With A Focus On Gene Sequencing Applications

Super Group (SGHC) Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) (the "Group" or "Super Group"), the parent company of Betway, a leading online sports betting and gaming business and Spin, the multi-brand online casino, today provided an update on its preliminary, unaudited fourth quarter and full-year 2024 performance.
The Group is pleased to announce that Q4 2024 is expected to be its strongest ever ex-US quarter with Total Revenue of ~€486 million and Adjusted EBITDA, a non-GAAP financial measure, of between €125 million and €130 million. During the quarter the Group projects to have set a number of new monthly ex-US records, with December being particularly impressive, achieving new highs for deposits and Total Revenue.
For the full-year, the Group expects to have surpassed its previously issued ex-US guidance targets of Total Revenue of €1.60 billion and Adjusted EBITDA of greater than €360 million.
New ex-US records were also expected to have been achieved in 2024 for both Total Revenue and Adjusted EBITDA, with Total Revenue growing by ~18% to ~€1.66 billion and Adjusted EBITDA growing by more than 50%, anticipated to be between €387 million and €392 million, a margin of greater than 23%.
The developing U.S. business is also anticipated to have delivered new records in the fourth quarter – October was an all-time high for Total Revenue, which was subsequently surpassed in both November and December. The expected Q4 2024 investment into the U.S. business is ~€11 million, which would bring the total investment for the year to ~€61 million. Given the reduced footprint and sole focus on iGaming in the U.S., this investment is expected to reduce materially in 2025.

Guidance

SGHC

Super Group Expects Q4 Revenue Of ~€486M Vs €404.65M Est, FY24 Revenue Of ~€1.66B Vs ~€1.613B Est

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) from Neutral to Neutral.

AGEN

HC Wainwright & Co. Reiterates Neutral on Agenusto Neutral

3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) reported better-than-expected fourth-quarter 2024 results and initiated 2025 <a href="https://www.benzinga.com/25/01/43096753/3m-reports-strong-q4-results-anticipates-growth-in-2025-with-improved-organic-sales-outlook">guidance on Tuesday.</a>
The company reported net sales of $6.01 billion, a slight increase of 0.13% year-over-year. Adjusted net sales totaled $5.808 billion, up 2.2% YoY, beating the consensus of $5.781 billion. Adjusted EPS was $1.68, down 2% YoY, beating the consensus of $1.66.
3M said it anticipates adjusted total sales growth of 0.5% to 1.5%, driven by adjusted organic sales growth of 2% to 3%. The company projects adjusted EPS in the range of $7.60 to $7.90 versus consensus of $7.78.
3M shares gained 4.2% to close at $146.89 on Tuesday.
These analysts made changes to their price targets on 3M following earnings announcement.
<ul>
<li>Wells Fargo analyst Joe O&#8217;Dea upgraded the rating for 3M from Equal-Weight to Overweight and raised the price target from $140 to $170.</li>
<li>JP Morgan analyst Stephen Tusa maintained 3M with an Overweight rating and raised the price target from $162 to $165.</li>
<li>Barclays analyst Julian Mitchell maintained the stock with an Overweight rating and boosted the price target from $161 to $165.</li>
</ul>

Considering buying MMM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="494" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22073705/image-151-1024x494.png" alt="" class="wp-image-744610" style="width:552px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22073705/image-151-1024x494.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22073705/image-151-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22073705/image-151-768x370.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22073705/image-151.png 1093w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/43123084/top-3-health-care-stocks-that-could-blast-off-this-quarter">Top 3 Health Care Stocks That Could Blast Off This Quarter</a></li>
</ul>

Earnings

3M Analysts Raise Their Forecasts After Better-Than-Expected Q4 Results

SeaStar Medical Holding Announces That Mayo Clinic Is Now Cleared To Enroll Subjects In The Company's Neutralize-aki Pivotal Trial, Increasing The Number Of Activated Sites To 15

Barclays analyst Nicholas Campanella maintains PPL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPL#NYSE">PPL</a>) with a Equal-Weight and lowers the price target from $34 to $33.

Barclays Maintains Equal-Weight on PPL, Lowers Price Target to $33

OFG Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OFG#NYSE">OFG</a>) reported quarterly earnings of $1.09 per share which beat the analyst consensus estimate of $0.96 by 13.54 percent. This is a 11.22 percent increase over earnings of $0.98 per share from the same period last year. The company reported quarterly sales of $149.138 million which beat the analyst consensus estimate of $147.401 million by 1.18 percent. This is a 3.93 percent increase over sales of $143.500 million the same period last year.

Earnings Beats

OFG Bancorp Q4 2024 GAAP EPS $1.09 Beats $0.96 Estimate, Sales $149.138M Beat $147.401M Estimate

STRM

Streamline Health Signed A New Contract For The Use Of RevID With A 120-bed, Oracle Health-ehr Based Health System With Facilities In Kentucky

Barclays analyst Eric Beaumont maintains NorthWestern Energy Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWE#NASDAQ">NWE</a>) with a Overweight and raises the price target from $56 to $57.

Barclays Maintains Overweight on NorthWestern Energy Group, Raises Price Target to $57

GAME

GameSquare Announced That It Has Extinguished Its Outstanding Convertible Note And Standby Equity Purchase Agreement With Yorkville Advisors Global

Comments

NMC HEALTH PLC ORD by NMC Health Plc.

NMC HEALTH PLC ORD by NMC Health Plc. (NMMCF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga